ArticleESMO open2025
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes.The oncologist · 2026Article
- Primary gastric melanoma in an Asian patient: a rare case report of early detection and therapeutic uncertainty.International journal of surgery case reports · 2026Article
- Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France.Dermatology and therapy · 2026Article
- A Systematic Review and Meta-Analysis of Surgical Feasibility and Outcomes Following Neoadjuvant Immune Checkpoint Inhibition in Resectable Stage III and IV Melanoma.Annals of surgical oncology · 2026Article
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Review
- Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.British journal of cancer · 2026Article
- Hydrogel-based delivery systems for cutaneous melanoma therapy: from chemical design and crosslinking strategies to structure-activity relationships.RSC advances · 2026Review
- A comparative review of economic evaluations for immune checkpoint inhibitors in early stage and advanced stage cancer: focusing on pembrolizumab.Frontiers in pharmacology · 2026Review
- Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions.Biomedicines · 2025Review
- A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition.Frontiers in immunology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
Abstract
backgroundTherapeutic advances have reshaped the treatment landscape for patients with resectable melanoma, particularly for those with stage IIB/C and stage III disease. In this article, we discuss the current status and future outlook of adjuvant immunotherapy for melanoma in Europe.
resultsAdjuvant immunotherapy offers significant benefits in terms of recurrence-free survival and distant metastasis-free survival. Uncertainties regarding overall survival (OS) benefits, however, remain. Trials such as Keynote-054, which are expected to provide crucial OS information, have delayed their final analyses until 2027. Additionally, real-world studies have raised questions about the correlation between recurrence-free survival/distant metastasis-free survival improvements observed in clinical trials and OS outcomes in routine clinical practice. These uncertainties have led to ongoing debates about the cost-effectiveness of adjuvant therapies, with disparities in reimbursement policies across Europe reflecting these concerns.
conclusionLooking ahead to 2028, adjuvant immunotherapy will remain a key option of comprehensive melanoma care, particularly for patients with stage IIB/C and stage III with micrometastatic disease, where neoadjuvant immunotherapy is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.